What Psychiatric Disorders Can Ketamine Treat?

I’ve spent fifteen years in medicine watching patients struggle with psychiatric conditions that don’t respond to conventional treatments. I’ve been in county hospitals, emergency rooms, and even practiced street medicine. Everywhere, people fall through every crack in the system. What I’ve seen, over and over, is that standard medications work for many people, but a significant number remain stuck in suffering despite trying everything their psychiatrists recommend.

Ketamine has changed that equation, and while this change isn’t for everyone with every condition, it’s certainly true for specific psychiatric disorders. I’m seeing, firsthand in my ketamine clinic in Livermore, something we rarely see in medicine: a genuinely different mechanism of action that can work when nothing else has.

This post serves as a comprehensive guide to ketamine for psychiatric disorders specifically. I’ll explain which conditions benefit most from ketamine therapy, which conditions require extreme caution or exclusion, and the neuroscience that explains why ketamine works differently than traditional psychiatric medications. If you’re exploring ketamine treatment options, it’s important to understand these distinctions.

Summary of Which Psychiatric Conditions Ketamine Therapy is Suitable for:

The table below outlines conditions that may benefit from ketamine therapy and identifies those for which it is contraindicated.

Information compiled by Dr. Elyas Parsa, DO, owner of Mind Balance Flow in Livermore, CA.

Psychiatric Disorders That Benefit Most from Ketamine

Treatment-Resistant Depression (TRD)

This is where the evidence is strongest. Treatment-resistant depression (TRD), defined as failing to respond to two or more adequate antidepressant trials, affects roughly 30% of people with major depression (2). For these patients, ketamine has shown response rates of 60-70% in clinical trials, with many experiencing improvement within 24 hours (3).

The FDA approved esketamine (Spravato) for TRD in 2019, validating ketamine’s role in depression treatment. We work with several insurance providers to increase access to Spravato, ensuring that as many people as possible are able to access this incredible treatment. –>Read more: Ketamine vs SSRIs for Depression

Suicidal Ideation

Perhaps ketamine’s most remarkable application is its rapid reduction of suicidal thoughts. Multiple studies demonstrate significant decreases in suicidal ideation within hours of ketamine administration, independent of its effects on overall depression severity (4). In my years of emergency medicine, I saw too many patients in acute suicidal crisis waiting days or weeks for traditional medications to take effect. Ketamine offers something we’ve never had before: a genuinely rapid intervention.

Anxiety Disorders

Generalized anxiety disorder, social anxiety, and panic disorder all show promising responses to ketamine therapy. The mechanism makes sense: anxiety disorders involve overactive threat-detection circuits and rigid thought patterns. Ketamine’s ability to enhance neural plasticity may help the brain “unstick” from anxious loops. A 2017 study found significant anxiety reduction in patients with treatment-resistant anxiety disorders following ketamine treatment (5). –>Read more about ketamine therapy for anxiety.

PTSD

Trauma literally changes brain structure, particularly in the amygdala and prefrontal cortex. PTSD involves memories that remain hyperactivated and resistant to normal extinction processes. Ketamine’s effect on the default mode network and its promotion of neuroplasticity may help the brain process and integrate traumatic memories more effectively. Research shows significant PTSD symptom reduction following ketamine treatment, with effects lasting beyond the acute medication period (6). –>Read more about ketamine therapy for PTSD.

OCD

Obsessive-compulsive disorder responds notoriously poorly to medication. Only about 40-60% of patients achieve meaningful improvement with SSRIs, and even responders often retain significant symptoms. Ketamine has shown rapid, significant reduction in OCD symptoms in multiple studies, sometimes within hours (7). For patients who’ve exhausted conventional options, this represents genuine hope.

Here’s my video explaining how ketamine works inside your brain:

Psychiatric Conditions Requiring Caution or Exclusion

I want to be direct here because responsible medicine requires honesty about limitations.

Bipolar Disorder

Standard antidepressants carry risks of triggering mania, limiting treatment options. The depressive episodes of bipolar disorder are often harder to treat than the manic episodes. Ketamine has demonstrated efficacy for bipolar depression specifically with a lower risk of mood switching than traditional antidepressants (8). Due to these complexities, ketamine treatment for bipolar requires careful monitoring and is best managed in coordination with a patient’s psychiatrist.

Active Psychosis and Schizophrenia

Ketamine is generally contraindicated in patients with active psychotic symptoms or a history of schizophrenia. Ketamine can induce transient psychotic-like experiences even in healthy individuals; in those predisposed to psychosis, these effects may be more pronounced or potentially destabilizing. Some research explores ketamine in very controlled settings for specific schizophrenia subtypes, but this remains investigational and is not appropriate for outpatient treatment (9).

Substance Use Disorder

While ketamine is promising for some substance use disorders when a patient is stable and in treatment, it is not appropriate during active, uncontrolled use. One reason is that ketamine itself carries its own dependence risk. So ketamine isn’t fully contraindicated for substance use disorder, but like everything else we get a thorough history and work with other providers as needed to ensure optimal outcomes.

Other Contraindications

Of course, there are other contraindications for ketamine treatment besides psychiatric conditions. I wrote an entire post specifically about what disqualifies someone from ketamine therapy, from hypertension to pregnancy and everything in between.  –>Read more: When is Ketamine Contraindicated? (Or, Who Shouldn’t Take Ketamine?)

Finding the Right Fit for Treatment

If you’re in Livermore, the Tri-Valley, or the broader Bay Area and exploring ketamine therapy for a psychiatric disorder, I encourage you to start with a consultation. We’ll review your history, discuss what’s worked and what hasn’t, and determine whether ketamine is appropriate for your specific situation.

Some patients aren’t candidates, and I’ll tell you directly if that’s the case. Others have conditions where ketamine offers genuine hope after years of limited options. The only way to know is through honest, thorough evaluation.

Schedule your free initial consultation and insurance review.

Sources

1. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-964. doi:10.1126/science.1190287
2. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. doi:10.1176/ajp.2006.163.11.1905
3. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134-1142. doi:10.1176/appi.ajp.2013.13030392
4. Wilkinson ST, Ballard ED, Bloch MH, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. Am J Psychiatry. 2018;175(2):150-158. doi:10.1176/appi.ajp.2017.17040472
5. Glue P, Medlicott NJ, Harland S, et al. Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. J Psychopharmacol. 2017;31(10):1302-1305. doi:10.1177/0269881117705089
6. Feder A, Parides MK, Murrough JW, et al. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681-688. doi:10.1001/jamapsychiatry.2014.62
7. Rodriguez CI, Kegeles LS, Levinson A, et al. Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder. Neuropsychopharmacology. 2013;38(12):2475-2483. doi:10.1038/npp.2013.150
8. Zarate CA Jr, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012;71(11):939-946. doi:10.1016/j.biopsych.2011.12.010
9. Beck K, Hindley G, Borber F, et al. Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(5):e204693. doi:10.1001/jamanetworkopen.2020.4693